Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of IOS.

OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2025 Luminary Awards in GI Cancer

October 30, 2025

Becca Fishman

OncLive® and the Ruesch Center at Georgetown Lombardi announce the 2025 Luminary Award winners in gastrointestinal cancers.

Dato-DXd Could Alter First-Line SOC in Immunotherapy-Ineligible TNBC

October 30, 2025

Chris Ryan

Rebecca Dent, MD, MSc, discusses data from the TROPION-Breast02 trial evaluating first-line Dato-Dxd in immunotherapy-ineligible triple-negative breast cancer

Tackling Drug Shortages in Hematologic Oncology Care Requires Nuance and Adaptability

October 30, 2025

Kyle Doherty

Harry P. Erba, MD, PhD, and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.

Allison Institute’s Third Annual Scientific Symposium Highlighted By Panel Discussion With Five Nobel Laureates

October 30, 2025

MD Anderson Cancer Center

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.

FDA Sets PDUFA Date for LNTH-2501 in Imaging of SSTR+ Neuroendocrine Tumors

October 30, 2025

Jax DiEugenio

The FDA set a March 29, 2026, PDUFA date for LNTH-2501, a PET imaging agent targeting SSTR-positive neuroendocrine tumors.

FDA Grants Orphan Drug Designation to DPTX3186 in Gastric Cancer

October 30, 2025

Chris Ryan

The FDA granted orphan drug designation to DPTX3186 in gastric cancer.

Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025

October 30, 2025

Courtney Flaherty

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

FDA Grants Orphan Drug Designation to Exosome-Based Therapy for Glioblastoma Multiforme

October 30, 2025

Chris Ryan

The FDA granted orphan drug designation to an exosome-based therapy for glioblastoma multiforme.

ESMO 2025 GI Cancer Data Highlight Emerging Precision Strategies and Treatment Avenues for Rare Cancers

October 30, 2025

Ashling Wahner

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.

Vepugratinib-Based Therapy Displays Potential in Metastatic FGFR3+ Urothelial Cancer

October 29, 2025

Chris Ryan

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

IO102-IO103 Plus Pembrolizumab Demonstrates Favorable Activity in PD-L1–High HNSCC and NSCLC

October 29, 2025

Jax DiEugenio

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

New Genomic Test Could Spare Some People With Melanoma From Lymph Node Biopsy Surgery

October 29, 2025

Mayo Clinic

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC

October 29, 2025

Chris Ryan

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

LEAP-012 Trial of Pembrolizumab/Lenvatinib/TACE to Close Following Missed OS End Point in Unresectable HCC

October 29, 2025

Caroline Seymour

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC

October 29, 2025

Courtney Flaherty

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.